Global Cyclodextrins In Pharma Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2022 –2029 |
 시장 규모(기준 연도) |
USD 270.40 Million |
 시장 규모(예측 연도) |
USD 370.06 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
글로벌 시클로덱스트린 in Pharma Market , 유형별(Β 시클로덱스트린, 2-하이드록시프로필-Β-시클로덱스트린, Α 시클로덱스트린, γ-시클로덱스트린, 무작위 메틸화된 Β-시클로덱스트린, 설포부틸에테르 Β-시클로덱스트린, 2-하이드록시프로필-Γ-시클로덱스트린), 구조(시클로덱스트린 접합체, 점막 접착성 약물 운반체, 시클로덱스트린 연관체, 양친매성 시클로덱스트린, 기타), 특성(친수성, 소수성 ), 형태(고체, 액체), 응용 분야(약물 용해도 및 용해, 약물 생물학적 이용 가능성, 약물 안전성, 약물 안정성, 기타), 치료 분야(통증 관리, 심혈관 질환, 행동 장애, 암 치료, 류마티스 관절염, 간질) 니만픽 질병 유형 C(NPC), 기타), 유통 채널(직접 입찰, 소매 판매, 기타) - 2029년까지의 산업 동향 및 예측
시장 분석 및 규모
최근 몇 년 동안 제약 시장의 사이클로덱스트린은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 사이클로덱스트린은 친유성 내부와 친수성 외부 껍질을 가진 전분 기반 당 분자입니다. 사이클로덱스트린은 노화 방지 특성으로 인해 화장품 제조업체에서 수요가 많습니다. 크림, 페이스 마스크, 로션과 같은 화장품 및 개인 관리 품목의 제조에 널리 사용되고 있으며 향후 몇 년 동안 시장 확장을 주도할 것으로 예상됩니다. 한편, 전 세계적으로 전반적인 면역력을 강화하는 식이 보충제의 인기가 높아지면서 예측 기간 동안 시장 확장이 촉진될 가능성이 높습니다.
Data Bridge Market Research는 2021년 제약 시장에서 사이클로덱스트린의 가치가 2억 7,040만 달러였으며 2029년까지 3억 7,006만 달러에 도달할 것으로 예상하고 2022년에서 2029년까지의 예측 기간 동안 4.00%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.
시장 정의
사이클로덱스트린은 알파-1,4 글리코시드 결합으로 연결된 포도당 서브유닛의 거대고리 고리로 구성된 복합 순환 당의 한 유형입니다. 사이클로덱스트린은 전분이 효소적으로 분해되어 간단한 분자로 형성됩니다. 사이클로덱스트린은 약물 전달의 용매 성분으로 제약 및 화학 산업에서 점점 더 많이 사용되고 있습니다. 사이클로덱스트린은 생물학적 시스템에서 소수성 약리 분자를 캡슐화하여 약물의 수용성, 안정성 및 생물학적 이용 가능성을 높이는 데 사용됩니다.
보고 범위 및 시장 세분화
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 (2019-2014까지 사용자 정의 가능) |
|
양적 단위 |
매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시 |
|
다루는 세그먼트 |
Type (Β Cyclodextrin, 2-Hydroxypropyl-Β-Cyclodextrin, Α Cyclodextrin, γ-Cyclodextrin, Randomly Methylated Β-Cyclodextrin, Sulfobutylether Β-Cyclodextrin, 2-Hydroxypropyl-Γ-Cyclodextrin), Structure (Cyclodextrin Conjugates, Mucoadhesive Drug Carriers, Cyclodextrin Associates, Amphiphilic Cyclodextrins, Others), Nature (Hydrophilic, Hydrophobic), Form (Solid, Liquid), Application (Drug Solubility and Dissolution, Drug Bioavailability, Drug Safety, Drug Stability, Others), Therapeutics Area (Pain Management, Cardiovascular Diseases, Behavioral Disorder, Cancer Therapy, Rheumatoid Arthritis, Epilepsy, Niemann Pick Disease Type C (NPC), Others), Distribution Channel (Direct Tender, Retail Sales, Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Cambrex Corporation (US), Cayman Chemical (US), Wellona Pharma (India), Wacker Chemie AG (Germany), Cyclolab (Hungary), Tocopharm Co. Limited (China), Roquette Frères (France), Midas Pharma GmbH (Germany), Ligand Pharmaceuticals Incorporated (US), Cyclo Therapeutics, Inc. (US), Zibo Qianhui biological technology co., ltd (China), Xi'an Deli Biochemical Industry Co., Ltd (China), Merck KGaA (Germany), Otto Chemie Pvt. Ltd. (India), VIO CHEMICALS (Switzerland), Ashland (US), TCI Chemicals (India) Pvt. Ltd. (Japan) |
|
Market Opportunities |
|
Cyclodextrins in Pharma Market Dynamics
Drivers
- Increasing consumption of dietary supplements
The rising consumption of dietary supplements is estimated to enhance the market's growth. Excipients such as cyclodextrin are utilized in pharmaceutical and nutraceutical formulations. As a result of the COVID-19 pandemic, doctors have prescribed a variety of antiviral medications to patients to help them fight the virus early on. The growing use of these medications has boosted cyclodextrin consumption, propelling market growth throughout the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of cyclodextrins in pharma market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the cyclodextrins in pharma market. Additionally, the rapidly changing consumer attitudes toward health and the growing use of cyclodextrins in renal diseases will also result in the expansion of cyclodextrins in pharma market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the cyclodextrins in pharma market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the cyclodextrins in pharma market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with drug distribution and development will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the cyclodextrins in pharma market. Additionally, strict regulatory policies coupled with the barriers to conducting diagnostics tests will restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This cyclodextrins in pharma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cyclodextrins in pharma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Cyclodextrins in pharma market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Cyclodextrins in Pharma Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The cyclodextrins in pharma market was hampered by the supply chain slowness. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. As a result, the market is projected to stabilize in the future.
Global Cyclodextrins in Pharma Market Scope
The cyclodextrins in pharma market is segmented on the basis of type, structure, nature, form, application, therapeutic areas and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Β Cyclodextrin
- 2-Hydroxypropyl-Β-Cyclodextrin
- Α Cyclodextrin
- γ-Cyclodextrin
- Randomly Methylated Β-Cyclodextrin
- Sulfobutylether Β-Cyclodextrin
- 2-Hydroxypropyl-Γ-Cyclodextrin
Structure
- Cyclodextrin Conjugates
- Mucoadhesive Drug Carriers
- Cyclodextrin Associates
- Amphiphilic Cyclodextrins
- Others
Nature
- Hydrophilic
- Hydrophobic
Form
- Solid
- Liquid
Application
- Drug Solubility and Dissolution
- Drug Bioavailability
- Drug Safety
- Drug Stability
- Others
Therapeutics Area
- Pain Management
- Cardiovascular Diseases
- Behavioral Disorder
- Cancer Therapy
- Rheumatoid Arthritis
- Epilepsy
- Niemann Pick Disease Type C (NPC)
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Cyclodextrins in Pharma Market Regional Analysis/Insights
The cyclodextrins in pharma market is analysed and market size insights and trends are provided by country, type, structure, nature, form, application, therapeutic areas and distribution channel as referenced above.
The countries covered in the cyclodextrins in pharma market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the cyclodextrins in the pharma market due to new cyclodextrin lead drugs in pharmacology in this region. Additionally, rising healthcare expenditure and growing demand of disease specific treatment will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to growing consumer demand for cyclodextrin compounds for pharmaceutical products in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel themarket's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cyclodextrins in Pharma Market Share Analysis
The cyclodextrins in pharma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cyclodextrins in pharma market.
Some of the major players operating in the cyclodextrins in pharma market are:
- Cambrex Corporation (US)
- Cayman Chemical (US)
- Wellona Pharma (India)
- Wacker Chemie AG (Germany)
- Cyclolab (Hungary)
- Tocopharm Co. Limited (China)
- Roquette Frères (France)
- Midas Pharma GmbH (Germany)
- Ligand Pharmaceuticals Incorporated (US)
- Cyclo Therapeutics, Inc. (US)
- Zibo Qianhui biological technology co., ltd (China)
- Xi'an Deli Biochemical Industry Co., Ltd (China)
- Merck KGaA (Germany)
- Otto Chemie Pvt. Ltd. (India)
- VIO CHEMICALS(스위스)
- 애슐랜드(미국)
- TCI Chemicals (인도) Pvt. Ltd. (일본)
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CYCLODEXTRINS IN PHARMA MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 THERAPEUTIC AREAS LIFELINE CURVE
2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.1 DBMR MARKET POSITION GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 REGULATIONS
5.1 FDA
5.2 JAPAN
6 IMPACT OF COVID-19 ON GLOBAL CYCLODEXTRIN IN PHARMA MARKET
6.1 PRICE IMPACT
6.2 IMPACT ON DEMAND
6.3 IMPACT ON SUPPLY CHAIN
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
6.5 CONCLUSION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING BIO AVAILABILITY OF POOR WATER SOLUBLE DRUGS
7.1.2 INCREASING DRUG STABILITY
7.1.3 USE OF CYCLODEXTRIN IN DRUG DELIVERY
7.1.4 LAUNCH OF FINISHED PRODUCTS OF CYCLODEXTRIN
7.1.5 RISING PREVALENCE OF CHRONIC DISEASES
7.2 RESTRAINTS
7.2.1 HIGH COSTS OF CYCLODEXTRIN
7.2.2 TOXICITY STUDIES OF CYCLODEXTRINS
7.3 OPPORTUNITIES
7.3.1 INCREASING RESEARCH OF CYCLODEXTRIN IN COVID-19 TREATMENT
7.3.2 RISING USE OF CYCLODEXTRIN IN RENAL DISEASES
7.3.3 RISING INVESTMENT ON RESEARCH ACTIVITIES
7.3.4 INCREASES AWARENESS ABOUT THE USE OF CYCLODEXTRIN IN PHARMA INDUSTRY
7.4 CHALLENGES
7.4.1 LIMITATION OF CYCLODEXTRIN IN OPTHALMIC USE
7.4.2 USE OF VARIOUS TECHNIQUES IN MANUFACTURING CYCLODEXTRIN
8 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE
8.1 OVERVIEW
8.1.1 Β CYCLODEXTRIN
8.1.2 2-HYDROXYPROPYL-Β-CYCLODEXTRIN
8.1.3 Α CYCLODEXTRIN
8.1.4 Γ-CYCLODEXTRIN
8.1.5 RANDOMLY METHYLATED Β-CYCLODEXTRIN
8.1.6 SULFOBUTYLETHER Β-CYCLODEXTRIN
8.1.7 2-HYDROXYPROPYL-Γ-CYCLODEXTRIN
9 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE
9.1 OVERVIEW
9.2 CYCLODEXTRIN CONJUGATES
9.2.1 POLYMERS
9.2.2 NANOSPONGES
9.3 MUCOADHESIVE DRUG CARRIERS
9.3.1 POLYETHYLENE-GLYCOL
9.3.2 CHITOSAN
9.3.3 ALGINATE
9.4 CYCLODEXTRIN ASSOCIATES
9.4.1 POLYPSEUDOROTAXANES
9.4.2 POLYROTAXANES
9.5 AMPHIPHILIC CYCLODEXTRINS
9.5.1 POLYSUBSTITUTED
9.5.2 MONOSUBSTITUTED
9.6 OTHERS
10 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY FORM
10.1 OVERVIEW
10.2 SOLID
10.3 LIQUID
11 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE
11.1 OVERVIEW
11.2 HYDROPHILIC
11.3 HYDROPHOBIC
12 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 DRUG SOLUBILITY AND DISSOLUTION
12.3 DRUG BIOAVAILABILITY
12.4 DRUG SAFETY
12.5 DRUG STABILITY
12.6 OTHERS
13 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS
13.1 OVERVIEW
13.2 PAIN MANAGEMENT
13.3 CARDIOVASCULAR DISEASES
13.4 BEHAVIORAL DISORDER
13.5 CANCER THERAPY
13.6 RHEUMATOID ARTHRITIS
13.7 EPILEPSY
13.8 NIEMANN PICK DISEASE TYPE C (NPC)
13.9 OTHERS
14 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
14.4 OTHERS
15 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY GEOGRAPHY
15.1 OVERVIEW
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.2 CANADA
15.2.3 MEXICO
15.3 EUROPE
15.3.1 GERMANY
15.3.2 FRANCE
15.3.3 U.K
15.3.4 ITALY
15.3.5 NETHERLANDS
15.3.6 SPAIN
15.3.7 RUSSIA
15.3.8 SWITZERLAND
15.3.9 BELGIUM
15.3.10 TURKEY
15.3.11 AUSTRIA
15.3.12 NORWAY
15.3.13 HUNGARY
15.3.14 LITHUANIA
15.3.15 IRELAND
15.3.16 POLAND
15.3.17 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 JAPAN
15.4.2 CHINA
15.4.3 INDIA
15.4.4 SOUTH KOREA
15.4.5 AUSTRALIA
15.4.6 SINGAPORE
15.4.7 MALAYSIA
15.4.8 THAILAND
15.4.9 INDONESIA
15.4.10 PHILIPPINES
15.4.11 VIETNAM
15.4.12 REST OF ASIA-PACIFIC
15.5 SOUTH AMERICA
15.5.1 BRAZIL
15.5.2 ARGENTINA
15.5.3 PERU
15.5.4 REST OF SOUTH AMERICA
15.6 MIDDLE EAST & AFRICA
15.6.1 SAUDI ARABIA
15.6.2 SOUTH AFRICA
15.6.3 UAE
15.6.4 ISRAEL
15.6.5 EGYPT
15.6.6 KUWAIT
15.6.7 REST OF MIDDLE EAST & AFRICA
16 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: GLOBAL
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
16.3 COMPANY SHARE ANALYSIS: EUROPE
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT
18 COMPANY PROFILE
18.1 ROQUETTE FRÈRES
18.1.1 COMPANY SNAPSHOT
18.1.2 COMPANY SHARE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.2 LIGAND PHARMACEUTICALS INCORPORATED
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 TECHNOLOGY PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 WACKER CHEMIE AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 MERCK KGAA
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 CYCLOLAB
18.5.1 COMPANY SNAPSHOT
18.5.2 PRODUCT PORTFOLIO
18.5.3 RECENT DEVELOPMENTS
18.6 CAMBREX CORPORATION
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 CAYMAN CHEMICAL
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS
18.8 CYCLO THERAPEUTICS, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 MIDAS PHARMA GMBH
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 TOCOPHARM CO. LIMITED
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 WELLONA PHARMA
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 XI'AN DELI BIOCHEMICAL INDUSTRY CO.,LTD.
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 ZIBO QIANHUI BIOLOGICAL TECHNOLOGY CO.,LTD
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
표 목록
LIST OF TABLES
TABLE 1 CURRENT ANTIVIRAL DRUGS TESTED OR IN DEVELOPMENT FOR TREATMENT OF COVID-19 AND PROPOSED CYCLODEXTRINS FOR FORMULATION ENHANCEMENT
TABLE 2 PRICE OF 25G BETA-CYCLODEXTRIN
TABLE 3 PRICE OF 100G BETA-CYCLODEXTRIN
TABLE 4 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2017-2027 (USD THOUSAND)
TABLE 5 GLOBA Β CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 6 GLOBAL 2-HYDROXYPROPYL-Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 7 GLOBAL Α CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 8 GLOBAL Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 9 GLOBAL RANDOMLY METHYLATED Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 10 GLOBAL SULFOBUTYLETHER Β-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 11 GLOBAL 2-HYDROXYPROPYL-Γ-CYCLODEXTRIN IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 12 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE 2019-2027 (USD THOUSAND)
TABLE 13 GLOBAL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)
TABLE 14 GLOBAL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 15 GLOBAL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION 2018-2027 (USD THOUSAND)
TABLE 16 GLOBAL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 17 GLOBAL CYCLODEXTRINS ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 18 GLOBAL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 19 GLOBAL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 20 GLOBAL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 21 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 22 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2019-2027 (USD THOUSAND)
TABLE 23 GLOBAL SOLID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 24 GLOBAL LIQUID IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 25 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2019-2027 (USD THOUSAND)
TABLE 26 GLOBAL HYDROPHILIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 27 GLOBAL HYDROPHOBIC IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 28 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2019-2027 (USD THOUSAND)
TABLE 29 GLOBAL DRUG SOLUBILITY AND DISSOLUTION IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 30 GLOBAL DRUG BIOAVAILABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 31 GLOBAL DRUG SAFETY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 32 GLOBAL DRUG STABILITY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 33 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 34 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2017-2027 (USD THOUSAND)
TABLE 35 GLOBA PAIN MANAGEMENT IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 36 GLOBA CARDIOVASCULAR DISEASES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 37 GLOBA BEHAVIORAL DISORDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 38 GLOBA CANCER THERAPY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 39 GLOBA RHEUMATOID ARTHRITIS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 40 GLOBA EPILEPSY IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 41 GLOBA NIEMANN PICK DISEASE TYPE C (NPC) IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 42 GLOBA OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 43 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)
TABLE 44 GLOBAL DIRECT TENDER IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 45 GLOBAL RETAIL SALES IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 46 GLOBAL OTHERS IN CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2019-2027 (USD THOUSAND)
TABLE 47 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 48 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 49 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 50 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 51 NORTH AMERICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 52 NORTH AMERICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 53 NORTH AMERICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 54 NORTH AMERICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 55 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 56 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 57 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 58 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 59 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 60 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 61 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 62 U.S. CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 63 U.S. CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 64 U.S. MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 65 U.S. AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 66 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 67 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 68 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 69 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 70 U.S. CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 71 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 72 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 73 CANADA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 74 CANADA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 75 CANADA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 76 CANADA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 77 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 78 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 79 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 80 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 81 CANADA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 82 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 83 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 84 MEXICO CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 85 MEXICO CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 86 MEXICO MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 87 MEXICO AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 88 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 89 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 90 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 91 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 92 MEXICO CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 93 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 94 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 95 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 96 EUROPE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 97 EUROPE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 98 EUROPE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 99 EUROPE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 100 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 101 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 102 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 103 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 104 EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 105 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 106 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 107 GERMANY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 108 GERMANY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 109 GERMANY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 110 GERMANY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 111 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 112 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 113 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 114 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 115 GERMANY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 116 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 117 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 118 FRANCE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 119 FRANCE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 120 FRANCE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 121 FRANCE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 122 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 123 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 124 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 125 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 126 FRANCE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 127 U.K CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 128 U.K CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 129 U.K CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 130 U.K CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 131 U.K MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 132 U.K AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 133 U.K CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 134 U.K CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 135 U.K CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 136 U.K CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 137 U.K CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 138 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 139 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 140 ITALY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 141 ITALY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 142 ITALY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 143 ITALY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 144 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 145 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 146 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 147 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 148 ITALY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 149 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 150 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 151 NETHERLANDS CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 152 NETHERLANDS CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 153 NETHERLANDS MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 154 NETHERLANDS AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 155 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 156 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 157 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 158 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 159 NETHERLANDS CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 160 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 161 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 162 SPAIN CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 163 SPAIN CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 164 SPAIN MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 165 SPAIN AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 166 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 167 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 168 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 169 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 170 SPAIN CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 171 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 172 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 173 RUSSIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 174 RUSSIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 175 RUSSIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 176 RUSSIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 177 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 178 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 179 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 180 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 181 RUSSIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 182 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 183 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 184 SWITZERLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 185 SWITZERLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 186 SWITZERLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 187 SWITZERLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 188 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 189 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 190 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 191 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 192 SWITZERLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 193 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 194 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 195 BELGIUM CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 196 BELGIUM CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 197 BELGIUM MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 198 BELGIUM AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 199 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 200 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 201 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 202 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 203 BELGIUM CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 204 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 205 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 206 TURKEY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 207 TURKEY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 208 TURKEY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 209 TURKEY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 210 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 211 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 212 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 213 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 214 TURKEY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 215 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 216 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 217 AUSTRIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 218 AUSTRIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 219 AUSTRIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 220 AUSTRIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 221 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 222 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 223 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 224 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 225 AUSTRIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 226 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 227 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 228 NORWAY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 229 NORWAY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 230 NORWAY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 231 NORWAY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 232 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 233 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 234 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 235 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 236 NORWAY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 237 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 238 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 239 HUNGARY CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 240 HUNGARY CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 241 HUNGARY MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 242 HUNGARY AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 243 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 244 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 245 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 246 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 247 HUNGARY CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 248 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 249 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 250 LITHUANIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 251 LITHUANIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 252 LITHUANIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 253 LITHUANIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 254 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 255 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 256 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 257 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 258 LITHUANIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 259 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 260 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 261 IRELAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 262 IRELAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 263 IRELAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 264 IRELAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 265 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 266 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 267 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 268 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 269 IRELAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 270 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 271 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 272 POLAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 273 POLAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 274 POLAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 275 POLAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 276 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 277 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 278 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 279 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 280 POLAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 281 REST OF EUROPE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 282 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 283 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 284 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 285 ASIA-PACIFIC CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 286 ASIA-PACIFIC CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 287 ASIA-PACIFIC MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 288 ASIA-PACIFIC AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 289 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 290 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 291 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 292 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 293 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 294 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 295 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 296 JAPAN CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 297 JAPAN CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 298 JAPAN MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 299 JAPAN AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 300 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 301 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 302 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 303 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 304 JAPAN CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 305 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 306 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 307 CHINA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 308 CHINA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 309 CHINA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 310 CHINA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 311 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 312 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 313 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 314 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 315 CHINA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 316 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 317 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 318 INDIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 319 INDIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 320 INDIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 321 INDIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 322 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 323 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 324 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 325 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 326 INDIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 327 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 328 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 329 SOUTH KOREA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 330 SOUTH KOREA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 331 SOUTH KOREA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 332 SOUTH KOREA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 333 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 334 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 335 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 336 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 337 SOUTH KOREA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 338 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 339 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 340 AUSTRALIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 341 AUSTRALIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 342 AUSTRALIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 343 AUSTRALIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 344 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 345 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 346 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 347 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 348 AUSTRALIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 349 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 350 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 351 SINGAPORE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 352 SINGAPORE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 353 SINGAPORE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 354 SINGAPORE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 355 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 356 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 357 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 358 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 359 SINGAPORE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 360 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 361 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 362 MALAYSIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 363 MALAYSIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 364 MALAYSIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 365 MALAYSIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 366 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 367 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 368 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 369 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 370 MALAYSIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 371 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 372 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 373 THAILAND CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 374 THAILAND CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 375 THAILAND MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 376 THAILAND AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 377 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 378 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 379 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 380 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 381 THAILAND CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 382 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 383 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 384 INDONESIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 385 INDONESIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 386 INDONESIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 387 INDONESIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 388 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 389 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 390 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 391 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 392 INDONESIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 393 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 394 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 395 PHILIPPINES CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 396 PHILIPPINES CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 397 PHILIPPINES MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 398 PHILIPPINES AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 399 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 400 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 401 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 402 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 403 PHILIPPINES CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 404 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 405 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 406 VIETNAM CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 407 VIETNAM CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 408 VIETNAM MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 409 VIETNAM AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 410 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 411 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 412 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 413 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 414 VIETNAM CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 415 REST OF ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 416 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 417 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 418 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 419 SOUTH AMERICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 420 SOUTH AMERICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 421 SOUTH AMERICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 422 SOUTH AMERICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 423 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 424 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 425 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 426 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 427 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 428 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 429 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 430 BRAZIL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 431 BRAZIL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 432 BRAZIL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 433 BRAZIL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 434 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 435 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 436 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 437 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 438 BRAZIL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 439 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 440 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 441 ARGENTINA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 442 ARGENTINA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 443 ARGENTINA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 444 ARGENTINA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 445 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 446 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 447 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 448 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 449 ARGENTINA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 450 PERU CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 451 PERU CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 452 PERU CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 453 PERU CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 454 PERU MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 455 PERU AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 456 PERU CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 457 PERU CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 458 PERU CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 459 PERU CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 460 PERU CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 461 REST OF SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 462 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY COUNTRY, 2018-2027 (USD THOUSAND)
TABLE 463 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 464 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 465 MIDDLE EAST & AFRICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 466 MIDDLE EAST & AFRICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 467 MIDDLE EAST & AFRICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 468 MIDDLE EAST & AFRICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 469 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 470 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 471 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 472 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 473 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 474 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 475 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 476 SAUDI ARABIA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 477 SAUDI ARABIA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 478 SAUDI ARABIA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 479 SAUDI ARABIA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 480 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 481 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 482 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 483 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 484 SAUDI ARABIA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 485 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 486 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 487 SOUTH AFRICA CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 488 SOUTH AFRICA CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 489 SOUTH AFRICA MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 490 SOUTH AFRICA AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 491 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 492 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 493 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 494 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 495 SOUTH AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 496 UAE CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 497 UAE CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 498 UAE CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 499 UAE CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 500 UAE MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 501 UAE AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 502 UAE CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 503 UAE CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 504 UAE CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 505 UAE CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 506 UAE CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 507 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 508 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 509 ISRAEL CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 510 ISRAEL CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 511 ISRAEL MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 512 ISRAEL AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 513 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 514 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 515 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 516 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 517 ISRAEL CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 518 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 519 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 520 EGYPT CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 521 EGYPT CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 522 EGYPT MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 523 EGYPT AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 524 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 525 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 526 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 527 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 528 EGYPT CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 529 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 530 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 531 KUWAIT CYCLODEXTRIN ASSOCIATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 532 KUWAIT CYCLODEXTRIN CONJUGATES IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 533 KUWAIT MUCOADHESIVE DRUG CARRIERS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 534 KUWAIT AMPHIPHILIC CYCLODEXTRINS IN CYCLODEXTRINS IN PHARMA MARKET, BY STRUCTURE, 2018-2027 (USD THOUSAND)
TABLE 535 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY NATURE, 2018-2027 (USD THOUSAND)
TABLE 536 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY FORM, 2018-2027 (USD THOUSAND)
TABLE 537 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY APPLICATION, 2018-2027 (USD THOUSAND)
TABLE 538 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSAND)
TABLE 539 KUWAIT CYCLODEXTRINS IN PHARMA MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 540 REST OF MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
그림 목록
LIST OF FIGURES
FIGURE 1 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SEGMENTATION
FIGURE 2 GLOBAL CYCLODEXTRINS IN PHARMA MARKET : DATA TRIANGULATION
FIGURE 3 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: DBMR MARKET POSITION GRID
FIGURE 10 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 13 INCREASING BIO AVAILABILITY OF POOR WATER SOLUBLE DRUGS AND INCREASES DRUG STABILITY IS DRIVING THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 14 B CYCLODEXTRIN SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN 2020 & 2027
FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET IN GLOBAL CYCLODEXTRINS IN PHARMA MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 16 GLOBAL CYCLODEXTRINS IN PHARMA MARKET, PIPELINE ANALYSIS
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CYCLODEXTRINS IN PHARMA MARKET
FIGURE 18 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, 2019
FIGURE 19 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, 2019-2027 (USD THOUSAND)
FIGURE 20 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 21 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, 2019
FIGURE 23 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, 2019-2027 (USD THOUSAND)
FIGURE 24 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, CAGR (2020-2027)
FIGURE 25 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY STRUCTURE, LIFELINE CURVE
FIGURE 26 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, 2019
FIGURE 27 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, 2019-2027 (USD THOUSAND)
FIGURE 28 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, CAGR (2020-2027)
FIGURE 29 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY FORM, LIFELINE CURVE
FIGURE 30 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, 2019
FIGURE 31 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, 2019-2027 (USD THOUSAND)
FIGURE 32 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, CAGR (2020-2027)
FIGURE 33 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY NATURE, LIFELINE CURVE
FIGURE 34 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, 2019
FIGURE 35 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, 2019-2027 (USD THOUSAND)
FIGURE 36 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY APPLICATION, CAGR (2020-2027)
FIGURE 37 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, 2019
FIGURE 39 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND)
FIGURE 40 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)
FIGURE 41 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE
FIGURE 42 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 43 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)
FIGURE 44 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 45 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 46 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 47 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2019)
FIGURE 48 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2020 & 2027)
FIGURE 49 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY REGION (2019 & 2027)
FIGURE 50 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 51 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 52 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 53 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 54 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 55 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 56 EUROPE CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 57 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 58 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 59 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 60 EUROPE CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 61 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 62 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 63 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 64 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 65 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 66 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 67 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 68 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 69 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 70 SOUTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 71 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: SNAPSHOT (2019)
FIGURE 72 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019)
FIGURE 73 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2020 & 2027)
FIGURE 74 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY COUNTRY (2019 & 2027)
FIGURE 75 MIDDLE EAST & AFRICA CYCLODEXTRINS IN PHARMA MARKET: BY TYPE (2020-2027)
FIGURE 76 GLOBAL CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)
FIGURE 77 NORTH AMERICA CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)
FIGURE 78 EUROPE CYCLODEXTRINS IN PHARMA MARKET: COMPANY SHARE 2019 (%)
FIGURE 79 ASIA-PACIFIC CYCLODEXTRINS IN PHARMA MARKETMARKET: COMPANY SHARE 2019 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
